<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262780</url>
  </required_header>
  <id_info>
    <org_study_id>502.453</org_study_id>
    <nct_id>NCT02262780</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 mg Telmisartan / 12.5 mg HCTZ to 80 mg Telmisartan / 12.5 mg HCTZ) and Multiple Oral Doses (80 mg Telmisartan / 12.5 mg HCTZ) of Drug in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Group 1:

      To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T40/H12.5 and
      T80/H12.5)

      Group 2:

      To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T80/H12.5 x 7
      days)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with clinically relevant findings in physical examination</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant findings in vital signs</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
    <description>blood pressure, pulse rate, body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant findings in 12-lead ECG</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant findings in clinical laboratory tests</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Global assessment of tolerability by the investigator</measure>
    <time_frame>up to 10 days after last drug administration</time_frame>
    <description>verbal rating scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of the analytes in plasma (Cmax)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve of the analytes in plasma (AUC)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to maximum concentration of the analytes in plasma (tmax)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant of the analytes in plasma (λz)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analytes in plasma (t1/2)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of the analytes in the body after po administration (MRTpo)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analytes in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of the analytes in plasma during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of HCTZ that is eliminated in urine from the time interval t1 to t2 (Aet1-t2)</measure>
    <time_frame>Up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of HCTZ excreted unchanged in urine from time point t1 to t2 (fet1-t2)</measure>
    <time_frame>Up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance of HCTZ in plasma from the time point t1 until the time point t2 (CLR, t1-t2)</measure>
    <time_frame>Up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum measured concentration of the analytes in plasma at steady state over a uniform dosing interval τ (Cmin,ss)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration of the analytes in plasma at steady state (Cavg)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of the analytes in plasma after multiple dose administration over a uniform dosing interval τ (RA)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single low dose Telmisartan with HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single high dose Telmisartan with HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple high dose Telmisartan with HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose of telmisartan</intervention_name>
    <arm_group_label>Single low dose Telmisartan with HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose of telmisartan</intervention_name>
    <arm_group_label>Single high dose Telmisartan with HCTZ</arm_group_label>
    <arm_group_label>Multiple high dose Telmisartan with HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCTZ</intervention_name>
    <arm_group_label>Single low dose Telmisartan with HCTZ</arm_group_label>
    <arm_group_label>Single high dose Telmisartan with HCTZ</arm_group_label>
    <arm_group_label>Multiple high dose Telmisartan with HCTZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males according to the following criteria: No finding deviating of clinical
             relevance and no evidence of a clinically relevant concomitant disease based upon a
             complete medical history, including the physical examination, vital signs (blood
             pressure (BP), pulse rate (PR), body temperature), 12-lead ECG, clinical laboratory
             tests

          -  Age ≥20 and Age ≤35 years

          -  Body Mass Index (BMI) ≥17.6 and BMI ≤26.4 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with &quot;Good Clinical Practice (GCP)&quot;

        Exclusion Criteria:

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Chronic or relevant acute infections

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Positive result for hepatitis B surface (HBs) antigen, anti hepatitis C virus (HCV)
             antibodies, Syphilitic test or HIV test

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  History of relevant orthostatic hypotension (mean standing SBP varies by ≥ 20 mmHg
             from mean supine systolic blood pressure (SBP) and/or mean standing diastolic blood
             pressure (DBP) varies by ≥ 10 mmHg from mean supine DBP), fainting spells or
             blackouts.

          -  History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)

          -  History of serious renal dysfunction

          -  History of bilateral renal artery stenosis or renal artery stenosis in a solitary
             kidney

          -  History of cerebrovascular disorder

          -  History of hyperkalemia

          -  Known hypersensitivity to any component of the formulation; known hypersensitivity to
             any other angiotensin II receptor antagonist; known hypersensitivity to sulfonamides
             or sulphonamide-derived drugs (e.g. thiazides)

          -  History of impaired glucose tolerance

          -  History of hypokalemia

          -  History of hyperuricemia

          -  Salt restriction therapy

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 7 days prior to administration or
             during the trial

          -  Participation in another trial with an investigational drug within four months or 6
             half-lives of the investigational drug, whichever is longer, prior to administration
             or during the trial

          -  Smoker (more than 20 cigarettes /day)

          -  Alcohol abuse

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within seven days prior to administration)

          -  Intake of alcohol within two days prior to administration

          -  Inability to comply with dietary regimen of study centre

          -  Inability to comply with smoking cessation during hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>October 10, 2014</last_update_submitted>
  <last_update_submitted_qc>October 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

